Drug Profile
Research programme: cancer therapeutics - EPI Pharmaceuticals
Alternative Names: PG-11000 Series; PG-11093; PG-11100 Series; PG-11122; PG-11144; SL11217; SL11218; SL11231; SL11237Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cellgate
- Developer EPI Pharmaceuticals
- Class Naphthoquinones; Polyamines; Porphyrins; Quinones
- Mechanism of Action Apoptosis stimulants; Cell division inhibitors; Histone deacetylase inhibitors; Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 14 Dec 2011 Progen Pharmaceuticals completes EPI Pharmaceuticals formation and transfers the epigenetic and cell proliferation assets to EPI
- 25 Feb 2011 Progen's cancer therapeutics are still at the preclinical stage for Cancer in Australia